UM

Browse/Search Results:  1-3 of 3 Help

Filters    
Selected(0)Clear Items/Page:    Sort:
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes Journal article
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2018,Volume: 14,Issue: 2,Page: 204-216
Authors:  Yang, Zheng;  Tam, Kin Yip
Favorite  |  View/Download:13/0  |  Submit date:2018/10/30
Combination  Egfr-tki  Nsclc  Chemotherapy  Targeted Therapy  Immunotherapy  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
CANCER LETTERS, 2018,Volume: 420,Page: 242-246
Authors:  Tang, Zheng-Hai;  Lu, Jin-Jian
Favorite  |  View/Download:14/0  |  Submit date:2018/10/30
Osimertinib  Azd9291  Egfr Tki  Resistant Mechanisms  Therapeutic Strategies  
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2018,Volume: 18,Issue: 4,Page: 550-555
Authors:  Tang Z.-H.;  Su M.-X.;  Guo X.;  Jiang X.-M.;  Jia L.;  Chen X.;  Lu J.-J.
Favorite  |  View/Download:5/0  |  Submit date:2018/12/28
Azd9291  Egfr  Ire1α  Lune Cancer  Nsclc  Osimertinib